Emerging drugs for the treatment of light chain amyloidosis
Systemic AL amyloidosis is a protein-misfolding disorder that is characterized by the deposition of insol...
Read moreResearch & Access Updates
Good News: FDA Panel Votes to Approve Belantamab Mafodotin
On Tuesday, July 14, the U.S. Food & Drug Administration’s ODAC (the Oncologic Drugs Advisory Committee)...
Read moreEncouraging News Regarding Phase 3 BOSTON Study Announced
On May 28, 2020, Karyopharm presented positive data from their BOSTON study at the American Society of Cl...
Read moreMelflufen Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating melflufen (melphalan fluf...
Read moreMyeloma Canada Research Network Consensus Guideline Consortium (MCRN-CGC)
What was the role of Myeloma Canada in creating these guidelines? Myeloma Canada provided logistic and...
Read moreApproval of Daratumumab in Combination with Lenalidomide and Dexamethasone for Newly Diagnosed Patients Who Are Transplant Ineligible
The Janssen Pharmaceutical Companies of Johnson & Johnson announced that Health Canada recently approved ...
Read more